Premium
Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin
Author(s) -
Herman G A,
Stein P P,
Thornberry N A,
Wagner J A
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100167
Subject(s) - sitagliptin , type 2 diabetes , dipeptidyl peptidase 4 inhibitor , sitagliptin phosphate , dipeptidyl peptidase 4 , medicine , pharmacology , dipeptidyl peptidase , focus (optics) , diabetes mellitus , endocrinology , chemistry , biochemistry , enzyme , physics , optics
Dipeptidyl peptidase‐4 (DPP‐4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes. 1 DPP‐4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain. 1 This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP‐4 inhibitor sitagliptin in the management of type 2 diabetes. Clinical Pharmacology & Therapeutics (2007) 81 , 761–767. doi: 10.1038/sj.clpt.6100167 ; published online 28 March 2007